...
首页> 外文期刊>Optics and Spectroscopy >Development and validation of a sensitive spectrofluorimetric method for the determination of cilazapril of human plasma, urine, in pure and pharmaceutical preparations
【24h】

Development and validation of a sensitive spectrofluorimetric method for the determination of cilazapril of human plasma, urine, in pure and pharmaceutical preparations

机译:开发和验证灵敏的分光光度法测定纯制剂和药物制剂中人血浆,尿中西拉普利的方法

获取原文
获取原文并翻译 | 示例

摘要

A selective and sensitive spectrofluorimetric method was developed and validated for the determination of cilazapril in human plasma urine, in pure and pharmaceutical preparations. The proposed method is based on derivatization using 1-dimethylaminonaphthalene-5-sulphonyl chloride (dansyl chloride) as fluorogenic agent and measuring the fluorescence of the products at emission wavelengths of 503 nm after excitation at 374 nm. The method was validated for linearity, limit of detection, limit of quantification, precision, accuracy, recovery. The calibration curves were linear over a concentration range of 100-500 and 50-250 ng/mL for plasma and urine, respectively. The limits of detection were calculated to be 0.26 and 31.59 ng/mL for plasma and urine, respectively. The proposed method was applied to study of cilazapril in pure, human plasma, urine, and pharmaceutical preparations.
机译:建立了选择性和灵敏的荧光分光光度法,并已用于纯血浆和药物制剂中人血浆尿中西拉普利的测定。所提出的方法基于使用1-二甲基氨基萘-5-磺酰氯(丹酰氯)作为荧光剂的衍生化,并在374 nm激发后在503 nm的发射波长下测量产物的荧光。验证了该方法的线性,检测限,定量限,精密度,准确度,回收率。血浆和尿液的浓度曲线分别在100-500 ng / mL和50-250 ng / mL的浓度范围内呈线性关系。血浆和尿液的检出限分别为0.26和31.59 ng / mL。拟议的方法被用于研究西拉普利在纯净的人血浆,尿液和药物制剂中的含量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号